IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies
2018
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI